Nevro Spine-Stim Patents Escape Re-Review By PTO
This article was originally published in The Gray Sheet
Executive Summary
The Patent Trial and Appeals Board won’t review a Nevro spinal cord stimulator patent after a challenge from Boston Scientific claimed the patent was invalid because it was too similar to prior knowledge in the field. The unusual decision not to even launch a so-called inter partes review in this case should be comforting to device patent holders, an attorney says.
You may also be interested in...
Nevro Will Take On Spinal Cord Stim Leaders As Senza Is Stamped 'Superior'
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.